Zobrazeno 1 - 10
of 163
pro vyhledávání: '"HIROO ISHIDA"'
Autor:
Ken‐ichi Fujita, Natsumi Matsumoto, Remi Murase, Kosuke Takeshima, Hiroo Ishida, Yutaro Kubota
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 10, Pp 1741-1747 (2023)
Abstract Regorafenib improves the survival of patients with metastatic colorectal cancer (mCRC); however, it is also characterized by detrimental dermal side effects that may require treatment cessation or modified dosing. In our previous prospective
Externí odkaz:
https://doaj.org/article/d0852674197946e3aea5afc90a221a27
Autor:
Yuta Nio, Hiroo Ishida, Natsumi Matsumoto, Sojiro Kusumoto, Yutaro Kubota, Takuya Tsunoda, Yasutsuna Sasaki, Ken-ichi Fujita
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Gefitinib is recommended as a first-line treatment option for elderly patients with non-small cell lung cancer (NSCLC). Because no pharmacokinetics of gefitinib have been examined, we prospectively assessed the pharmacokinetics of
Externí odkaz:
https://doaj.org/article/d782a4040fdf4d7288eb955e6906f4fd
Autor:
Jun Arai, Yumi Otoyama, Ken-ichi Fujita, Kaku Goto, Masayuki Tojo, Atsushi Katagiri, Hisako Nozawa, Yutaro Kubota, Takehiro Takahashi, Hiroo Ishida, Takuya Tsunoda, Natsumi Matsumoto, Keita Ogawa, Ryo Nakagawa, Ryosuke Muroyama, Naoya Kato, Hitoshi Yoshida
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background To evaluate the effect of regorafenib on soluble MHC class I polypeptide-related sequence A (MICA) (sMICA) level in vitro. In addition, we clinically examined whether its plasma levels were associated with regorafenib activity in
Externí odkaz:
https://doaj.org/article/beacc506008f4c9b88f6ed901d1eff5b
Autor:
Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, Tomonori Makiguchi, Megumi Inaba, Takeshi Honda, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Yasushi Fukuda, Masayuki Yasugi, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: The standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC study. Although multiple Japanese phase II studies have shown high effic
Externí odkaz:
https://doaj.org/article/feac51af35784b0ea75161b640b0afa8
Autor:
Koki Katayama, Shimon Nakashima, Hiroo Ishida, Yutaro Kubota, Masataka Nakano, Tatsuki Fukami, Yasutsuna Sasaki, Ken-ichi Fujita, Miki Nakajima
Publikováno v:
Non-coding RNA Research, Vol 6, Iss 3, Pp 123-129 (2021)
Single nucleotide polymorphisms in genes encoding microRNAs (miRNA-SNPs) may affect the maturation steps of miRNAs or target mRNA recognition, leading to changes in the expression of target mRNAs to cause gain- or loss-of-function changes. Several mi
Externí odkaz:
https://doaj.org/article/19faf567fce240339e0b270504a3c810
Autor:
Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, Megumi Inaba, Ryosuke Ochiai, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Yosuke Miyamoto, Toshihide Yokoyama, Chiaki Matsumoto, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main rea
Externí odkaz:
https://doaj.org/article/f543356f2cde488fb62f7c3ac3464ba7
Autor:
Kiyoshi Sato, Hiroaki Shimamoto, Yumi Mochizuki, Hideaki Hirai, Hirofumi Tomioka, Risa Shimizu, Eriko Marukawa, Haruhisa Fukayama, Ryoichi Yoshimura, Hiroo Ishida, Hiroyuki Harada
Publikováno v:
Journal of Otolaryngology - Head and Neck Surgery, Vol 48, Iss 1, Pp 1-7 (2019)
Abstract Background Malignancies occur in approximately 1:1000 pregnancies; the most common being breast (46%) and hematological (18%) malignancies. Oral cancers account for only 2% of all cancers in pregnant women, and there are no standard guidelin
Externí odkaz:
https://doaj.org/article/aa6d3ede0245453bba08d764c60f592c
Autor:
Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Hisashi Tanaka, Megumi Inaba, Terunobu Haruyama, Junya Nakamura, Takayuki Kishikawa, Masanao Nakashima, Keiichi Iwasa, Keiichi Fujiwara, Tadashi Kohyama, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Hiroo Ishida, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Toshihide Yokoyama, Kenichi Gemba, Takeshi Tsuda, Hideyuki Nakagawa, Hirotaka Ono, Tetsuo Shimizu, Morio Nakamura, Sojiro Kusumoto, Ryuji Hayashi, Hiroki Shirasaki, Nobuaki Ochi, Keisuke Aoe, Nobuhiro Kanaji, Kosuke Kashiwabara, Hiroshi Inoue, Nobuhiko Seki
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Based on the results of the PACIFIC study, chemoradiotherapy followed by 1-year consolidation therapy with durvalumab was established as the standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC). Howeve
Externí odkaz:
https://doaj.org/article/96f6f9e07bb84541842c0f47686bf218
Autor:
Takuhiro Yamaguchi, Tempei Miyaji, Hirotoshi Iihara, Yasushi Ohno, Takako Eguchi Nakajima, Chikatoshi Katada, Takashi Kawaguchi, Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, Honda Kazunori, Yusuke Inada, Hitoshi Arioka, Hajime Morita, Naoya Hida, Mitsuhiro Sugawara, Shuichi Nawata, Hiroo Ishida, Takashi Tsuda
Publikováno v:
BMJ Open, Vol 10, Iss 12 (2020)
Introduction Dexamethasone (DEX) is administered for multiple days to prevent chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy (HEC); however, its notorious side effects have been widely reported. Althoug
Externí odkaz:
https://doaj.org/article/b035f200f8874e499b4b1025fbd8bd51
Autor:
Ryotaro Ohkuma, Erica Yada, Shumpei Ishikawa, Daisuke Komura, Hidenobu Ishizaki, Koji Tamada, Yutaro Kubota, Kazuyuki Hamada, Hiroo Ishida, Yuya Hirasawa, Hirotsugu Ariizumi, Etsuko Satoh, Midori Shida, Makoto Watanabe, Rie Onoue, Kiyohiro Ando, Junji Tsurutani, Kiyoshi Yoshimura, Takehiko Yokobori, Tetsuro Sasada, Takeshi Aoki, Masahiko Murakami, Tomoko Norose, Nobuyuki Ohike, Masafumi Takimoto, Masahiko Izumizaki, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0226707 (2020)
Pancreatic cancer has an extremely poor prognosis, and identification of novel predictors of therapeutic efficacy and prognosis is urgently needed. Chemoresistance-related molecules are correlated with poor prognosis and may be effective targets for
Externí odkaz:
https://doaj.org/article/2516b1d1f4a1457cbd0daf1c90b6b292